Form 4: Vaccinex CEO and Related Entity Report Share Transactions
SEC Form 4 Filing
Vaccinex CEO Maurice Zauderer and Vaccinex (Rochester), L.L.C. reported transactions involving the acquisition of common stock and holdings of derivative securities.
Summary
- Maurice Zauderer, the President and CEO of Vaccinex, Inc., reported acquiring 46,153 shares of common stock at a price of $3.25 per share on November 14, 2024.
- The report also details holdings of common stock indirectly owned through the Jeremy C. Zauderer Trust (1,016 shares), the Jordan M. Zauderer Trust (1,011 shares), and Vaccinex (Rochester), L.L.C. (297,941 shares).
- Additionally, the report outlines various stock options held by Mr. Zauderer, with exercise prices ranging from $8.21 to $1,491 and expiration dates extending to 2034.
- Vaccinex (Rochester), L.L.C. also reported holding 170,475 warrants with an exercise price of $5.636 and an expiration date of September 18, 2029.
Sentiment
Score: 5
Explanation: The document is a neutral report of insider transactions, with no inherent positive or negative sentiment. It is a routine filing.
Industry Context
This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the holdings and trading activities of key executives and related entities.
Comparison to Industry Standards
- The reporting of insider transactions is a standard practice for all publicly listed companies in the US, as mandated by the SEC.
- The level of detail provided in this Form 4 is consistent with what is expected for such filings, including the reporting of direct and indirect ownership, as well as derivative securities.
- Companies like Regeneron, Amgen, and Biogen also regularly file similar forms when their executives or major shareholders trade company stock.
Stakeholder Impact
- The filing provides transparency to shareholders regarding the transactions of the company's CEO and related entities.
- The information may influence investor sentiment, but the impact is likely to be minimal as it is a routine disclosure.
Key Dates
| Date | Description |
|---|---|
| 09/18/2024 | Expiration date of warrants held by Vaccinex (Rochester), L.L.C. |
| 11/14/2024 | Date of common stock acquisition by Maurice Zauderer. |
| 11/18/2024 | Date of filing of the SEC Form 4. |
| 12/23/2025 | Exercisable date for one of the stock options held by Maurice Zauderer. |
| 02/24/2025 | Exercisable date for one of the stock options held by Maurice Zauderer. |
| 04/02/2031 | Exercisable date for one of the stock options held by Maurice Zauderer. |
| 04/01/2032 | Exercisable date for one of the stock options held by Maurice Zauderer. |
| 03/30/2028 | Exercisable date for one of the stock options held by Maurice Zauderer. |
| 03/21/2034 | Exercisable date for one of the stock options held by Maurice Zauderer. |
Keywords
Vaccinex, VCNX, Maurice Zauderer, stock options, warrants, insider trading, share acquisition, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.